Plasma Apelin and ADMA Levels in Patients with Essential Hypertension

REFERENCES

• Boucher J, Masri B, Daviaud D, Gesta S, Guigne C, Mazzucotelli A. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2004;146:1764–1771.
   Web of Science ®Google Scholar
• Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998;251:471–476.
   PubMed Web of Science ®Google Scholar
• Lee DK, Cheng R, Nguyen T, Fan T, Kariyawasam AP, Liu Y. Characterization of apelin, the ligand for the APJ receptor. J Neurochem 2000;74:34–41.
   PubMed Web of Science ®Google Scholar
• Kleinz MJ, Davenport AP. Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 2004;118:119–125.
   PubMed Web of Science ®Google Scholar
• Szokodi I, Tavi P, Foldes G, Voutilainen-Myllyla S, Ilves M, Tokola H. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002;91:434–440.
   PubMed Web of Science ®Google Scholar
• Cheng X, Cheng XS, Pang CC. Venous dilator effect of apelin, an endogenous peptide ligand for the orphan APJ receptor, in conscious rats. Eur J Pharmacol 2003;470:171–175.
   PubMed Web of Science ®Google Scholar
• Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W. The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 2002;291:1208–1212.
   PubMed Web of Science ®Google Scholar
• Kasai A, Shintani N, Oda M, Kakuda M, Hashimoto H, Matsuda T. Apelin is a novel angiogenic factor in retinal endothelial cells. Biochem Biophys Res Commun 2004;325:395–400.
   PubMed Web of Science ®Google Scholar
• Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology 2005;146:231–236.
   PubMed Web of Science ®Google Scholar
• Japp AG, Cruden NL, Amer DA, Li VK, Goudie EB, Johnston NRl. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008;52:908–913.
   PubMed Web of Science ®Google Scholar
• Salcedo A, Garijo J, Monge L, Fernández N, Luis García-Villalón A, Sánchez Turrión V. Apelin effects in human splanchnic arteries. Role of nitric oxide and prostanoids. Regul Pept 2007;144:50–55.
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001;99:87–92.
   PubMed Web of Science ®Google Scholar
• Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S. Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 2004;279:26274–26279.
   PubMed Web of Science ®Google Scholar
• Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008;116:289–292.
   PubMed Web of Science ®Google Scholar
• Tasci I, Dogru T, Naharci I, Erdem G, Yilmaz MI, Sonmez A. Plasma apelin is lower in patients with elevated LDL-cholesterol. Exp Clin Endocrinol Diabetes 2007;115:428–432.
   PubMed Web of Science ®Google Scholar
• Földes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308:480–485.
   PubMed Web of Science ®Google Scholar
• Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S. Apelin: A new plasma marker of cardiopulmonary disease. Regul Pept 2006;133:134–138.
   PubMed Web of Science ®Google Scholar
• Małyszko J, Małyszko JS, Koźminski P, Myśliwiec M. Apelin and cardiac function in hemodialyzed patients: possible relations? Am J Nephrol 2006;26:121–126.
   PubMed Web of Science ®Google Scholar
• Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005;46:186–202.
   PubMed Web of Science ®Google Scholar
• Cooke JP. ADMA: Its role in vascular disease. Vasc Med 2005;10:S11–17.
   PubMed Web of Science ®Google Scholar
• Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005;46:518–523.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Sonmez A, Saglam M, Qureshi AR, Carrero JJ, Caglar K. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J Am Soc Nephrol 2008;19:388–395.
   PubMed Web of Science ®Google Scholar
• Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm BO, Winkelmann BR. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem 2007;53:273–283.
   PubMed Web of Science ®Google Scholar
• Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113–2117.
   PubMed Web of Science ®Google Scholar
• Yilmaz MI, Saglam M, Sonmez A, Caglar K, Cakir E, Kurt Y. Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan. Blood Purif 2007;25:327–335.
   PubMed Web of Science ®Google Scholar
• Tasci I, Erdem G, Ozgur G, Tapan S, Dogru T, Genc H. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2009;204:222–228.
   PubMed Web of Science ®Google Scholar
• Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499–502.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Katugampola SD, Maguire JJ, Matthewson SR, Davenport AP. Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man. Br J Pharmacol. 2001;132:1255–1260.
   PubMed Web of Science ®Google Scholar
• Hou YC, Janczuk A, Wang PG. Current trends in the development of nitric oxide donors. Curr Pharm Des 1999;5:417–441.
   PubMed Web of Science ®Google Scholar
• Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201–1203.
   PubMed Web of Science ®Google Scholar
• Stuhlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002;287:1420–1426.
   PubMed Web of Science ®Google Scholar
• Böger RH, Bode-Böger SM, Szuba A, Tsao PS, Chan JR, Tangphao O. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98:1842–1847.
   PubMed Web of Science ®Google Scholar
• Oguz A, Uzunlulu M. Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome. Int Heart J 2008;49:303–311.
   PubMed Web of Science ®Google Scholar